June 5, 2017 08:26 AM EDT
R&D

Roche’s ‘suc­cess’ with its big Per­je­ta/Her­ceptin PhI­II falls flat at AS­CO, but it’s a boost for Puma

John Carroll

Editor & Founder

CHICA­GO — Roche her­ald­ed a suc­cess for its close­ly-watched com­bi­na­tion breast can­cer study of Per­je­ta and Her­ceptin at AS­CO on Mon­day, but once the

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

GSK sues Mod­er­na over mR­NA vac­cine patents, seeks 'rea­son­able roy­al­ty'

J&J trims pipeline, in­clud­ing two mid-stage neu­ro­science stud­ies

J&J’s medtech slump con­tin­ues, im­prove­ments not ex­pect­ed un­til 2025

Pfiz­er part­ners with mol­e­c­u­lar glue start­up Tri­ana in $49M up­front deal

Mary­land biotech gets green light for stem cell-de­rived ther­a­py for di­a­betes, aim­ing to com­pete with Ver­tex

sponsored

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

A service from the Financial Times